Arrhythmias & electrophysiologyRandomised controlled trial
Device-Assisted vs Standard Valsalva Maneuver for Terminating Supraventricular Tachycardia
- Randomised controlled trial
- single-centre
- open-label
Authors' conclusion
Per the results of this randomized clinical trial, the handheld Valsalva assist device significantly enhances VM effectiveness, providing a potentially implementable solution for SVT management.
Study context
- Population
- Patients with supraventricular tachycardia (SVT) (aged 16–80 years) undergoing electrophysiological study, induced SVT, tertiary hospital210 in primary analysis
- Participants
- 212 patients
- Comparison
- Device-assisted Valsalva maneuver (VM) vs standard VM
- Device-assisted VMn = 106
- Standard VMn = 106reference
- Primary endpoint
- Immediate cardioversion success (12-lead ECG-confirmed sinus rhythm within 1 minute) postintervention
- Follow-up
- Within 1 minute
Primary result
As reported in the abstract
Conversion to sinus rhythm within 1 minute after 2 VMs
Odds ratio
4.16
95% CI 2.36–7.47
P < 0.001
Events by treatment group
Device-assisted VM vs Standard VM
OR 4.16 (95% CI 2.36–7.47); P < 0.001
Original publication
Device-Assisted vs Standard Valsalva Maneuver for Terminating Supraventricular Tachycardia. JAMA Cardiol. Published 1 March 2026. doi:10.1001/jamacardio.2025.5489
Summarised from the published abstract; every number is checked against it